Impact of obesity on low density lipoprotein plasmatic levels 6 weeks after an acute coronary syndrome.
| Autor: | Bourgeois E; Departments of Endocrinology., Benchalkha D; Pharmacy., Brobst M; Pharmacy., Herman F; Medical Information., Molinari N; Medical Information., Breuker C; Pharmacy., Chapet N; Pharmacy., Roubille F; Cardiology, University Hospital Center of Montpellier, Montpellier, France., Sultan A; Departments of Endocrinology. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiovascular endocrinology & metabolism [Cardiovasc Endocrinol Metab] 2024 Dec 06; Vol. 14 (1), pp. e00320. Date of Electronic Publication: 2024 Dec 06 (Print Publication: 2025). |
| DOI: | 10.1097/XCE.0000000000000320 |
| Abstrakt: | Introduction: Cardiovascular disease is the leading cause of death. One of the main factors is obesity, which is on the rise. LDL levels below 0.55 g/L are recommended after ACS. To date, there are no specific recommendations for obese subjects. Objective: The primary objective was to assess the impact of obesity on LDL-c target attainment 6 weeks after initiation of statin therapy in subjects admitted for ACS. The secondary objectives were to assess the evolution of cholesterol levels and to characterize lipid-lowering treatments. Methods: The single-center observational study took place at Montpellier University Hospital and included patients admitted to the ICU for ACS not treated with statins (T0). Biological tests were performed at 6 weeks. At 3 months, a telephone call was made by two pharmacists to collect the results of their biological work-up and any therapeutic modifications. Results: The results were analyzed on 286 patients. A total of 39.5% were overweight and 22.7% obese. After hospitalization, 95.4% were prescribed statins. At 6 weeks, LDL cholesterol averaged 1.58 mmol/L, lower in subjects with a BMI greater than 30 kg/m 2 (1.32 mmol/L). On average, 49.46% of subjects reached the LDL cholesterol target, with obese subjects achieving a higher rate of 64.9%. There was no significant difference in the prescription of lipid-lowering treatments between the two groups. Conclusion: Despite high-intensity statin prescription, the target was achieved by 67.6% of obese subjects and 44.8% of subjects with a BMI of less than 30 kg/m 2 . This shows that post-SCA management needs to be reinforced for the general population. Competing Interests: François Roubille: declares honoraria for lectures/consulting byh: Astra Zeneca, Servier, Boehringer, Astra Zeneca, Vifor, Bayer, Pfizer, Novartis, Servier, Novonordisk, Air liquid, Abbott, QuidelOrtho, Newcard, MSD, BMS, Sanofi, Alnylam, Zoll, Implicity, GSK, BMS. Ariane Sultan: Servier, Viatris, Amgen, Sanofi. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|